SCHEMBL31522959

SCHEMBL31522959

COC(=O)c1ccc(C(C)(F)F)nc1NC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 1/20 0.47
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39
TUBA1C Q9BQE3 1/20 0.39
TUBB6 Q9BUF5 1/20 0.39
TUBB2B Q9BVA1 1/20 0.39
TUBB1 Q9H4B7 1/20 0.39
ACVR1B P36896 1/20 0.37
TGFBR1 P36897 1/20 0.37
ACVRL1 P37023 1/20 0.37
CFTR P13569 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1514112 0.82 ATR (0.56) ATRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31523668 0.80 ATR (0.48) ATRACVR1BTGFBR1ACVRL1GAA
SCHEMBL29110222 0.75 TUBB4A (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1513971 0.75 BCHE (0.46) ATRGAAMEN1KMT2A
SCHEMBL31523311 0.75 CFTR (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL4351188 0.74 ATR (0.56) ATRGAAKDM4EPOLBRAB9A
SCHEMBL12133786 0.73 ATR (0.49) ATRACVR1BTGFBR1ACVRL1SYK
SCHEMBL38663529 0.73 ATR (0.49) ATRACVR1BTGFBR1ACVRL1CFTR
SCHEMBL38661717 0.73 ATR (0.49) ATRACVR1BTGFBR1ACVRL1CFTR
SCHEMBL29656731 0.72 TUBB4A (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-11-13 US disclosed
WO-2025054488-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2025-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES WRN, RECQL, BLM ATR 173/4885TUBB4A 3916/4885TUBB 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.